HermioneG
2022-01-06
Awesome!
Pfizer Upgraded by BofA; Regeneron, Amgen Downgraded<blockquote>美国银行上调辉瑞评级；再生元、安进评级下调</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":695603841,"tweetId":"695603841","gmtCreate":1641434340682,"gmtModify":1641434340858,"author":{"id":3581581151725380,"idStr":"3581581151725380","authorId":3581581151725380,"authorIdStr":"3581581151725380","name":"HermioneG","avatar":"https://static.tigerbbs.com/449ae31dcb8cfcd4dcedab9bc5dec8aa","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Awesome!</p></body></html>","htmlText":"<html><head></head><body><p>Awesome!</p></body></html>","text":"Awesome!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/695603841","repostId":1133241429,"repostType":4,"repost":{"id":"1133241429","kind":"news","pubTimestamp":1641434274,"share":"https://www.laohu8.com/m/news/1133241429?lang=zh_CN&edition=full","pubTime":"2022-01-06 09:57","market":"us","language":"en","title":"Pfizer Upgraded by BofA; Regeneron, Amgen Downgraded<blockquote>美国银行上调辉瑞评级；再生元、安进评级下调</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133241429","media":"TheStreet","summary":"'We expect the Pfizer narrative to shift to benefits of its Covid-19 success in stepped up pipeline/","content":"<p><html><head></head><body>'We expect the Pfizer narrative to shift to benefits of its Covid-19 success in stepped up pipeline/portfolio investments,' BofA said.</p><p><blockquote><html><head></head><body>美国银行表示，我们预计辉瑞的叙述将转向其在新冠肺炎疫情中的成功所带来的好处，即加强管道/组合投资。</body></html></blockquote></p><p>Pharmaceutical giant Pfizer was upgraded to buy by Bank of America, while it downgraded biotechs Regeneron Pharmaceuticals to underperform and Amgen to neutral.</p><p><blockquote>美国银行将制药巨头辉瑞的评级上调至买入，同时将生物技术公司再生元制药的评级下调至表现不佳，将安进的评级下调至中性。</blockquote></p><p>Pfizer was raised from neutral, Regeneron was downgraded from neutral, and Amgen was lowered from buy.</p><p><blockquote>辉瑞从中性上调，再生元从中性下调，安进从买入下调。</blockquote></p><p>BofA lifted its Pfizer price target to $70 from $59, while cutting its Regeneron price target to $575 from $675 and its Amgen price target to $255 from $285.</p><p><blockquote>美国银行将辉瑞目标价从59美元上调至70美元，同时将再生元目标价从675美元下调至575美元，将安进目标价从285美元下调至255美元。</blockquote></p><p>BofA upgraded Pfizer based on “expectations of a dramatic rollout of Paxlovid (an oral Covid-19 therapy) in 2022 and significant investments in the pipeline,” wrote analyst Geoff Meacham.</p><p><blockquote>分析师杰夫·米查姆(Geoff Meacham)写道，美国银行上调辉瑞的评级是基于“对Paxlovid（一种口服Covid-19疗法）将在2022年大幅推出的预期以及对该产品的重大投资”。</blockquote></p><p>“Since 2020, investors have focused squarely on Pfizer's success in battling Covid-19, namely through vaccines and now oral agents,” he said.</p><p><blockquote>“自2020年以来，投资者一直关注辉瑞在抗击Covid-19方面的成功，即通过疫苗和现在的口服药物，”他说。</blockquote></p><p>“However, in 2022 we expect the Pfizer narrative to shift to the benefits of its Covid-19 success in the form of stepped up pipeline/portfolio investments.</p><p><blockquote>“然而，到2022年，我们预计辉瑞的叙述将以加强管道/投资组合投资的形式转向其Covid-19成功的好处。</blockquote></p><p>As for Regeneron, its stock “outperformed in 2021 based primarily on a spike in [Covid treatment] REGEN-COV revenues,” Meacham wrote. “Looking to 2022, however, the Covid-19 contribution should be minimal, which we think could change the narrative on shares.”</p><p><blockquote>Meacham写道，至于Regeneron，其股票“在2021年表现出色，主要是基于[Covid治疗]REGEN-COV收入的激增”。“然而，展望2022年，Covid-19的贡献应该很小，我们认为这可能会改变股票的叙述。”</blockquote></p><p>“In addition, while Eylea [a macular degeneration drug] and Dupixent [an eczema drug] should continue to grow in 2022, consensus expectations aren’t conservative with competitive headwinds on the horizon.”</p><p><blockquote>“此外，虽然Eylea（一种黄斑变性药物）和Dupixent（一种湿疹药物）应该会在2022年继续增长，但由于竞争阻力即将到来，共识预期并不保守。”</blockquote></p><p>When it comes to Amgen, “due to lingering Covid-19 headwinds and net pricing pressures, AMGN shares underwhelmed in 2021,” Meacham said.</p><p><blockquote>谈到安进，“由于挥之不去的Covid-19逆风和净定价压力，AMGN股价在2021年表现不佳，”Meacham表示。</blockquote></p><p>“Looking to 2022, we'd argue that growth skepticism is likely to persist until Amgen demonstrates a clear return to strong, volume-driven revenue upside for a number of key franchises including Otezla,” which treats plaque psoriasis.</p><p><blockquote>“展望2022年，我们认为，增长怀疑可能会持续下去，直到安进证明包括治疗斑块型银屑病的Otezla在内的许多主要特许经营权明显恢复强劲、销量驱动的收入增长”。</blockquote></p><p>Pfizer closed higher 2.02% at $55.63, Regeneron closed lower 3.52% at $595.12; and Amgen closed lower 1.2% at $225.15 on Wednesday.</p><p><blockquote>辉瑞收高2.02%，报55.63美元，再生元收低3.52%，报595.12美元；安进周三收盘下跌1.2%，至225.15美元。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Upgraded by BofA; Regeneron, Amgen Downgraded<blockquote>美国银行上调辉瑞评级；再生元、安进评级下调</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Upgraded by BofA; Regeneron, Amgen Downgraded<blockquote>美国银行上调辉瑞评级；再生元、安进评级下调</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2022-01-06 09:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>'We expect the Pfizer narrative to shift to benefits of its Covid-19 success in stepped up pipeline/portfolio investments,' BofA said.</p><p><blockquote><html><head></head><body>美国银行表示，我们预计辉瑞的叙述将转向其在新冠肺炎疫情中的成功所带来的好处，即加强管道/组合投资。</body></html></blockquote></p><p>Pharmaceutical giant Pfizer was upgraded to buy by Bank of America, while it downgraded biotechs Regeneron Pharmaceuticals to underperform and Amgen to neutral.</p><p><blockquote>美国银行将制药巨头辉瑞的评级上调至买入，同时将生物技术公司再生元制药的评级下调至表现不佳，将安进的评级下调至中性。</blockquote></p><p>Pfizer was raised from neutral, Regeneron was downgraded from neutral, and Amgen was lowered from buy.</p><p><blockquote>辉瑞从中性上调，再生元从中性下调，安进从买入下调。</blockquote></p><p>BofA lifted its Pfizer price target to $70 from $59, while cutting its Regeneron price target to $575 from $675 and its Amgen price target to $255 from $285.</p><p><blockquote>美国银行将辉瑞目标价从59美元上调至70美元，同时将再生元目标价从675美元下调至575美元，将安进目标价从285美元下调至255美元。</blockquote></p><p>BofA upgraded Pfizer based on “expectations of a dramatic rollout of Paxlovid (an oral Covid-19 therapy) in 2022 and significant investments in the pipeline,” wrote analyst Geoff Meacham.</p><p><blockquote>分析师杰夫·米查姆(Geoff Meacham)写道，美国银行上调辉瑞的评级是基于“对Paxlovid（一种口服Covid-19疗法）将在2022年大幅推出的预期以及对该产品的重大投资”。</blockquote></p><p>“Since 2020, investors have focused squarely on Pfizer's success in battling Covid-19, namely through vaccines and now oral agents,” he said.</p><p><blockquote>“自2020年以来，投资者一直关注辉瑞在抗击Covid-19方面的成功，即通过疫苗和现在的口服药物，”他说。</blockquote></p><p>“However, in 2022 we expect the Pfizer narrative to shift to the benefits of its Covid-19 success in the form of stepped up pipeline/portfolio investments.</p><p><blockquote>“然而，到2022年，我们预计辉瑞的叙述将以加强管道/投资组合投资的形式转向其Covid-19成功的好处。</blockquote></p><p>As for Regeneron, its stock “outperformed in 2021 based primarily on a spike in [Covid treatment] REGEN-COV revenues,” Meacham wrote. “Looking to 2022, however, the Covid-19 contribution should be minimal, which we think could change the narrative on shares.”</p><p><blockquote>Meacham写道，至于Regeneron，其股票“在2021年表现出色，主要是基于[Covid治疗]REGEN-COV收入的激增”。“然而，展望2022年，Covid-19的贡献应该很小，我们认为这可能会改变股票的叙述。”</blockquote></p><p>“In addition, while Eylea [a macular degeneration drug] and Dupixent [an eczema drug] should continue to grow in 2022, consensus expectations aren’t conservative with competitive headwinds on the horizon.”</p><p><blockquote>“此外，虽然Eylea（一种黄斑变性药物）和Dupixent（一种湿疹药物）应该会在2022年继续增长，但由于竞争阻力即将到来，共识预期并不保守。”</blockquote></p><p>When it comes to Amgen, “due to lingering Covid-19 headwinds and net pricing pressures, AMGN shares underwhelmed in 2021,” Meacham said.</p><p><blockquote>谈到安进，“由于挥之不去的Covid-19逆风和净定价压力，AMGN股价在2021年表现不佳，”Meacham表示。</blockquote></p><p>“Looking to 2022, we'd argue that growth skepticism is likely to persist until Amgen demonstrates a clear return to strong, volume-driven revenue upside for a number of key franchises including Otezla,” which treats plaque psoriasis.</p><p><blockquote>“展望2022年，我们认为，增长怀疑可能会持续下去，直到安进证明包括治疗斑块型银屑病的Otezla在内的许多主要特许经营权明显恢复强劲、销量驱动的收入增长”。</blockquote></p><p>Pfizer closed higher 2.02% at $55.63, Regeneron closed lower 3.52% at $595.12; and Amgen closed lower 1.2% at $225.15 on Wednesday.</p><p><blockquote>辉瑞收高2.02%，报55.63美元，再生元收低3.52%，报595.12美元；安进周三收盘下跌1.2%，至225.15美元。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/pfizer-upgraded-regeneron-amgen-downgraded-bofa\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","AMGN":"安进","REGN":"再生元制药公司"},"source_url":"https://www.thestreet.com/investing/pfizer-upgraded-regeneron-amgen-downgraded-bofa","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133241429","content_text":"'We expect the Pfizer narrative to shift to benefits of its Covid-19 success in stepped up pipeline/portfolio investments,' BofA said.Pharmaceutical giant Pfizer was upgraded to buy by Bank of America, while it downgraded biotechs Regeneron Pharmaceuticals to underperform and Amgen to neutral.Pfizer was raised from neutral, Regeneron was downgraded from neutral, and Amgen was lowered from buy.BofA lifted its Pfizer price target to $70 from $59, while cutting its Regeneron price target to $575 from $675 and its Amgen price target to $255 from $285.BofA upgraded Pfizer based on “expectations of a dramatic rollout of Paxlovid (an oral Covid-19 therapy) in 2022 and significant investments in the pipeline,” wrote analyst Geoff Meacham.“Since 2020, investors have focused squarely on Pfizer's success in battling Covid-19, namely through vaccines and now oral agents,” he said.“However, in 2022 we expect the Pfizer narrative to shift to the benefits of its Covid-19 success in the form of stepped up pipeline/portfolio investments.As for Regeneron, its stock “outperformed in 2021 based primarily on a spike in [Covid treatment] REGEN-COV revenues,” Meacham wrote. “Looking to 2022, however, the Covid-19 contribution should be minimal, which we think could change the narrative on shares.”“In addition, while Eylea [a macular degeneration drug] and Dupixent [an eczema drug] should continue to grow in 2022, consensus expectations aren’t conservative with competitive headwinds on the horizon.”When it comes to Amgen, “due to lingering Covid-19 headwinds and net pricing pressures, AMGN shares underwhelmed in 2021,” Meacham said.“Looking to 2022, we'd argue that growth skepticism is likely to persist until Amgen demonstrates a clear return to strong, volume-driven revenue upside for a number of key franchises including Otezla,” which treats plaque psoriasis.Pfizer closed higher 2.02% at $55.63, Regeneron closed lower 3.52% at $595.12; and Amgen closed lower 1.2% at $225.15 on Wednesday.","news_type":1,"symbols_score_info":{"REGN":0.9,"PFE":0.9,"AMGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2914,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/695603841"}
精彩评论